PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis

References

• Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104–114. doi:10.1016/j.jhep.2019.03.013
   PubMed Web of Science ®Google Scholar
• Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96. doi:10.1097/SLA.0b013e318176c4d3
   PubMed Web of Science ®Google Scholar
• Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950–1958. doi:10.1093/annonc/mdz402
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer D, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. doi:10.1056/NEJMoa0908721
   PubMed Web of Science ®Google Scholar
• de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368–1378. doi:10.1056/nejm199910283411807
   PubMed Web of Science ®Google Scholar
• Spolverato G, Bagante F, Weiss M, et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017;115(6):696–703. doi:10.1002/jso.24569
   PubMed Web of Science ®Google Scholar
• Ebata T, Ercolani G, Alvaro D, Ribero D, Di Tommaso L, Valle JW. Current status on cholangiocarcinoma and gallbladder cancer. Liver Cancer. 2016;6(1):59–65. doi:10.1159/000449493
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, Phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. doi:10.1016/s1470-2045(19)30626-6
   PubMed Web of Science ®Google Scholar
• Asaoka Y, Ijichi H, Koike KPD-1. Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;373(20):1979. doi:10.1056/NEJMc1510353
   PubMed Web of Science ®Google Scholar
• Mody K, Starr J, Saul M, et al. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol. 2019;10(6):1099–1109. doi:10.21037/jgo.2019.08.08
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190–2198. doi:10.1002/ijc.33013
   PubMed Web of Science ®Google Scholar
• Zhou J, Fan J, Shi G, et al. 56P Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: a Phase II clinical trial. Ann Oncol. 2020;31:S262–S263. doi:10.1016/j.annonc.2020.08.034
   Web of Science ®Google Scholar
• Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, Phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–621. doi:10.1016/s2468-1253(19)30086-x
   PubMed Web of Science ®Google Scholar
• Jian Z, Fan J, Shi G-M, et al. Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-arm, Phase 2 trial. J Clin Oncol. 2021;39(15_suppl):4099. doi:10.1200/JCO.2021.39.15_suppl.4099
   Web of Science ®Google Scholar
• Do-Youn O, Aiwu Ruth HE, Qin S, et al. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin (Gemcis) in Patients (Pts) with Advanced Biliary Tract Cancer (BTC): TOPAZ-1. ASCO Gastrointestinal Cancers Symposium; 2022. doi:10.1200/JCO.2022.40.4_suppl.378
   Google Scholar
• Neuzillet C. First-line chemotherapy plus immunotherapy in biliary tract cancer. Lancet Gastroenterol Hepatol. 2022;7(6):496–497.
   PubMed Web of Science ®Google Scholar
• Armato SG 3rd, Nowak AK. Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1). J Thorac Oncol. 2018;13(7):1012–1021. doi:10.1016/j.jtho.2018.04.034
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhou A, Zhang W, Jiang Z, Qu W. A phase Ib study of anlotinib plus TQB2450 as second-line therapy for advanced biliary tract adenocarcinoma. J Clin Oncol. 2021;39:4075. doi:10.1200/JCO.2021.39.15_suppl.4075
   Web of Science ®Google Scholar
• Villanueva L, Lwin Z, Chung H, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. J Clin Oncol. 2021;39:4080. doi:10.1200/JCO.2021.39.15_suppl.4080
   Web of Science ®Google Scholar
• Wang D, Yang X, Long J, et al. The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study. Front Oncol. 2021;11:646979. doi:10.3389/fonc.2021.646979
   PubMed Web of Science ®Google Scholar
• Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol. 2021;18(8):527–540. doi:10.1038/s41571-021-00496-y
   PubMed Web of Science ®Google Scholar
• Rahma OE, Stephen Hodi F. The Intersection between Tumor Angiogenesis and Immune Suppression. Clin Cancer Res. 2019;25(18):5449–5457.
   PubMed Web of Science ®Google Scholar
• Shigeta K, Datta M, Hato T, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology. 2020;71(4):1247–1261. doi:10.1002/hep.30889
   PubMed Web of Science ®Google Scholar
• Tada Y, Togashi Y, Kotani D, et al. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 + T cells in the tumor microenvironment. J Immunother Cancer. 2018;6(1):106. doi:10.1186/s40425-018-0403-1
   PubMed Web of Science ®Google Scholar
• Song Y, Yang F, Xie Q, et al. Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol. 2020;25(11):1956. doi:10.3389/fimmu.2020.01956
   Web of Science ®Google Scholar
• Liu T, Li W, Yu Y, et al. 53P Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: a preliminary analysis of safety and efficacy of an open-label phase II clinical study. Ann Oncol. 2020;31:S261. doi:10.1016/j.annonc.2020.08.031
   Web of Science ®Google Scholar
• Wei-Di Y, Sun G, Li J, et al. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019;28(452):66–70.
   Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.
   PubMed Web of Science ®Google Scholar